Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1217408.RA2JdFKdwFoSV-CH6mTo-BIEJJLQrJ-3cXhXu3wHVF3Gw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1217408.RA2JdFKdwFoSV-CH6mTo-BIEJJLQrJ-3cXhXu3wHVF3Gw130_assertion type Assertion NP1217408.RA2JdFKdwFoSV-CH6mTo-BIEJJLQrJ-3cXhXu3wHVF3Gw130_head.
- NP1217408.RA2JdFKdwFoSV-CH6mTo-BIEJJLQrJ-3cXhXu3wHVF3Gw130_assertion description "[Targeting PLK1 in OS with NMS-P937 in association with conventional chemotherapeutic drugs may be a new interesting therapeutic option, since this approach has proved to be active against drug resistant cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217408.RA2JdFKdwFoSV-CH6mTo-BIEJJLQrJ-3cXhXu3wHVF3Gw130_provenance.
- NP1217408.RA2JdFKdwFoSV-CH6mTo-BIEJJLQrJ-3cXhXu3wHVF3Gw130_assertion evidence source_evidence_literature NP1217408.RA2JdFKdwFoSV-CH6mTo-BIEJJLQrJ-3cXhXu3wHVF3Gw130_provenance.
- NP1217408.RA2JdFKdwFoSV-CH6mTo-BIEJJLQrJ-3cXhXu3wHVF3Gw130_assertion SIO_000772 25193492 NP1217408.RA2JdFKdwFoSV-CH6mTo-BIEJJLQrJ-3cXhXu3wHVF3Gw130_provenance.
- NP1217408.RA2JdFKdwFoSV-CH6mTo-BIEJJLQrJ-3cXhXu3wHVF3Gw130_assertion wasDerivedFrom befree-2016 NP1217408.RA2JdFKdwFoSV-CH6mTo-BIEJJLQrJ-3cXhXu3wHVF3Gw130_provenance.
- NP1217408.RA2JdFKdwFoSV-CH6mTo-BIEJJLQrJ-3cXhXu3wHVF3Gw130_assertion wasGeneratedBy ECO_0000203 NP1217408.RA2JdFKdwFoSV-CH6mTo-BIEJJLQrJ-3cXhXu3wHVF3Gw130_provenance.